{"doi":"10.1039\/b508908e","coreId":"135306","oai":"oai:bradscholars.brad.ac.uk:10454\/4115","identifiers":["oai:bradscholars.brad.ac.uk:10454\/4115","10.1039\/b508908e"],"title":"Design and synthesis of a DNA-crosslinking azinomycin analogue","authors":["Pors, Klaus","Casely-Hayford, Maxwell A.","Hartley, J.A.","Patterson, Laurence H.","Searcey, M."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2005","abstract":"NoThe azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relatively unstable and unlikely to progress as therapeutic candidates. A prototype analogue 4 with more clinical potential has been designed and synthesised and incorporates the epoxide function of the azinomycins and a nitrogen mustard. Two further analogues 5 and 6 that can alkylate DNA but cannot crosslink the duplex have also been synthesised. Compound 4 crosslinks DNA efficiently at nM concentrations. Compounds 4\u00bf6 were submitted to the NCI 60 cell line screen and have similar antitumour activity, although 4 is slightly less active than the non-crosslinking compounds. These observations will be important in the design of further azinomycin analogues with antitumour activity","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":null,"rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/4115<\/identifier><datestamp>\n                2016-08-18T17:05:31Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nDesign and synthesis of a DNA-crosslinking azinomycin analogue<\/dc:title><dc:creator>\nPors, Klaus<\/dc:creator><dc:creator>\nCasely-Hayford, Maxwell A.<\/dc:creator><dc:creator>\nHartley, J.A.<\/dc:creator><dc:creator>\nPatterson, Laurence H.<\/dc:creator><dc:creator>\nSearcey, M.<\/dc:creator><dc:subject>\nDNA-crosslinking<\/dc:subject><dc:subject>\nAzinomycin Analogue<\/dc:subject><dc:subject>\nCancer Therapeutics<\/dc:subject><dc:description>\nNo<\/dc:description><dc:description>\nThe azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relatively unstable and unlikely to progress as therapeutic candidates. A prototype analogue 4 with more clinical potential has been designed and synthesised and incorporates the epoxide function of the azinomycins and a nitrogen mustard. Two further analogues 5 and 6 that can alkylate DNA but cannot crosslink the duplex have also been synthesised. Compound 4 crosslinks DNA efficiently at nM concentrations. Compounds 4\u00bf6 were submitted to the NCI 60 cell line screen and have similar antitumour activity, although 4 is slightly less active than the non-crosslinking compounds. These observations will be important in the design of further azinomycin analogues with antitumour activity.<\/dc:description><dc:date>\n2009-12-16T09:38:17Z<\/dc:date><dc:date>\n2009-12-16T09:38:17Z<\/dc:date><dc:date>\n2005<\/dc:date><dc:type>\nArticle<\/dc:type><dc:type>\nNo full-text available in the repository<\/dc:type><dc:identifier>\nPors, K., Casely-Hayford, M., Hartley, J.A. and Patterson, L.H. (2005). Design and synthesis of a DNA-crosslinking azinomycin analogue. Organic & Biomolecular Chemistry. Vol. 3, No. 19, pp. 3585-3589.<\/dc:identifier><dc:identifier>\n90000186<\/dc:identifier><dc:identifier>\n90015088<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/4115<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1039\/b508908e<\/dc:relation>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1039\/b508908e"],"year":2005,"topics":["DNA-crosslinking","Azinomycin Analogue","Cancer Therapeutics"],"subject":["Article","No full-text available in the repository"],"fullText":null}